CD229 CAR T-cell therapy treated tumours had lasting response mice
Researchers have created a CAR T-cell therapy which targets the CD229 molecule expressed on all multiple myeloma cells and killed human tumour cells in mice.
List view / Grid view
Researchers have created a CAR T-cell therapy which targets the CD229 molecule expressed on all multiple myeloma cells and killed human tumour cells in mice.
A research team has shown that a key difference between neurogenic and non-neurogenic tissues is cross-linking proteins causing stiffness, a discovery that could be used to create new brain injury therapies.
Researchers have identified that in leukaemia, mutated receptors allow blood stem cells to activate one another without the proper signal and suggest this discovery could lead to targeted novel therapies.
Drug Target Review explores research that suggests the microbiome could be a therapeutic target for major depressive disorder and what treatment options are now in the pipeline as a result of this association.
Research into age-related chronic inflammatory disorders has identified an ‘off switch’ on the NLRP3 inflammasome that could be targeted in new therapies.
Researchers have found that half of public and charity support for health research over the past 14 years has been for studying the cause and progression of disease.
Researchers have revealed that inhibiting IL-17 could prevent the effects of autoimmune diseases, including multiple sclerosis.
To address the receptor dysfunction associated with several neurological diseases, scientists have provided novel insights into a protein-protein interaction that could lead to more effective treatments.
Research into alternative stem cell sources has identified urine derived renal progenitor cells (UdRPCs) as a possible option for use in regenerative kidney therapies in the future.
Researchers have screened thousands of drugs to discover that C1 effectively blocks the production of amyloid fibrils, so could be an effective therapeutic.
Research into the structure of the drug-integrin complex has enabled the creation of drugs which inhibit integrin as effectively as currently used compounds, without causing excessive bleeding.
Research into the M2 proton channel of influenza B has revealed its structure, which the team hope can aid in the development of targeted therapeutics to block the channel and treat the condition.
Research has shown that human metapneumovirus uses RNA methylation to hide from the immune system and that knocking out this methylation creates a mutant strain which acts like a vaccine.
Scientists have found that a molecule present in our blood, called C4BP (β-), could be used in a therapeutic capacity for lupus as well as potentially other autoimmune disorders.
The mechanism that prevents destruction of cancer cells by CAR T-cell therapy has been identified by researchers in Pennsylvania.